Christian Angermayer, founder and chairman of Atai Life Sciences ATAI, told Twitter that he bought 1 million shares of his company.
“Many #biotech stocks are cheap at the moment. In my opinion, Atai Life Sciences AG stands out though for two reasons: the size of the market (unfortunately) & the fact that the compounds historically selected by atai have prior human or anecdotal evidence. Hence I have increased my stake via a capped call of 1m shares as filing today,” he explained on LinkedIn.
At the current stock price, the transaction by Angermayer is around $4 million, a show of trust in the potential of his company. Through his investment firm, Apeiron Investment Group, Angermayer is set on standing by what he wrote last December and “put his money where his mouth is.”
These last few months have been kind to Atai, upping its Compass Pathways CMPS stake from 19.4 to 20.8 percent, and with a positive financial results report for 2021.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.